{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:28:03Z","timestamp":1790198883202,"version":"4.1.0"},"reference-count":107,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1517\/13543784.16.1.59","type":"journal-article","created":{"date-parts":[[2006,12,7]],"date-time":"2006-12-07T14:37:51Z","timestamp":1165502271000},"page":"59-72","source":"Crossref","is-referenced-by-count":45,"title":["An update on pharmacological approaches to neurodegenerative diseases"],"prefix":"10.1517","volume":"16","author":[{"given":"Roberto","family":"Scatena","sequence":"first","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe E","family":"Martorana","sequence":"additional","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bottoni","sequence":"additional","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Botta","sequence":"additional","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pastore","sequence":"additional","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Giardina","sequence":"additional","affiliation":[{"name":"Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2006,12,7]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105173442006"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.627"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1067"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1066"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1025"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1525"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1742"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.08.004"},{"key":"e_1_3_1_11_1","first-page":"1385","volume":"14","author":"BEHER","year":"2005","unstructured":"BEHER D, GRAHAM SL: Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. Expert Opin. Investig. Drugs (2005) 14(11):1385-409.","journal-title":"Expert"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1495"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1435"},{"key":"e_1_3_1_14_1","first-page":"1","volume":"15","author":"MARTINEZ","year":"2006","unstructured":"MARTINEZ A, CASTRO A: Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs (2006) 15(1):1-12.","journal-title":"Expert"},{"key":"e_1_3_1_15_1","first-page":"197","volume":"3","author":"GOZES","year":"2006","unstructured":"GOZES I, SPIVAK-POHIS I: Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr. Alzheimer Res. (2006) 3:197-199.","journal-title":"Curr"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2006.01.004"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000089285"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-5a"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.4.817"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd938"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00502-7"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212694200"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2000.3559"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519120-00002"},{"key":"e_1_3_1_25_1","first-page":"78","volume":"7","author":"RATTRAY","year":"2005","unstructured":"RATTRAY M: Technology evaluation: colostrinin, ReGen. Curr. Opin. Mol. Ther. (2005) 7:78-84.","journal-title":"Curr"},{"key":"e_1_3_1_26_1","first-page":"17","volume":"6","author":"BILIKIEWICZ","year":"2004","unstructured":"BILIKIEWICZ A, GAUS W: Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimers Dis. (2004) 6:17-26.","journal-title":"J."},{"key":"e_1_3_1_27_1","first-page":"35","volume":"3","author":"LABIE","year":"2006","unstructured":"LABIE C, CANOLLE B, CHATELIN S et al.: Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis. Curr. Alzheimer Res. (2006) 3:35-36.","journal-title":"Curr"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14660820410019602"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.11.1469"},{"key":"e_1_3_1_30_1","first-page":"337","volume":"88","author":"GASPARINI","year":"2004","unstructured":"GASPARINI L, RUSCONI L, XU H et al.: Modulation of \u03b2-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. (2004) 88:337-348.","journal-title":"J."},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2004.12.029"},{"key":"e_1_3_1_32_1","first-page":"2246","volume":"22","author":"JANTZEN","year":"2002","unstructured":"JANTZEN PT, CONNOR KE, DICARLO G et al.: Microglial activation and \u03b2-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. (2002) 22:2246-2254.","journal-title":"J."},{"key":"e_1_3_1_33_1","first-page":"74","volume":"176","author":"GREIG","year":"2000","unstructured":"GREIG NH, DE MICHELI E, HOLLOWAY HW et al.: The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. Suppl. (2000) 176:74-84.","journal-title":"Acta"},{"key":"e_1_3_1_34_1","first-page":"281","volume":"2","author":"GREIG","year":"2005","unstructured":"GREIG NH, SAMBAMURTI K, YU QS, BROSSI A, BRUINSMA GB, LAHIRI DK: An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. (2005) 2:281-290.","journal-title":"Curr"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.10.029"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2004.tb00011.x"},{"key":"e_1_3_1_37_1","first-page":"82","volume":"6","author":"LYNCH","year":"2006","unstructured":"LYNCH G: Glutamate-based therapeutic approach: ampakine. Curr. Opin. Pharmacol. (2006) 6:82-88.","journal-title":"Curr"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00013-2"},{"key":"e_1_3_1_39_1","first-page":"277","volume":"313","author":"XIA","year":"2005","unstructured":"XIA YF, KESSLER M, ARAI AC: Positive \u03b1-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmissionin the thalamus and hippocampus. J. Pharmacol. Exp. Ther. (2005) 313:277-285.","journal-title":"J."},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03654.x"},{"key":"e_1_3_1_41_1","first-page":"233","volume":"341","author":"MARUYAMA","year":"2003","unstructured":"MARUYAMA W, WEINSTOCK M, YOUDIM MB et al.: Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]- ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. (2003) 341:233-236.","journal-title":"Neurosci"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.07.030"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.01.019"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/75761"},{"key":"e_1_3_1_45_1","first-page":"5572","volume":"22","author":"COLLINSON","year":"2002","unstructured":"COLLINSON N, KUENZI F, JAROLIMEK W et al.: Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the \u03b15 subunit of the GABAA receptor. J. Neurosci. (2002) 22:5572-5580.","journal-title":"J."},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.06.070"},{"key":"e_1_3_1_47_1","first-page":"715","volume":"46","author":"DUNBAR","year":"2006","unstructured":"DUNBAR G, DEMAZIERES A, MONREAL A et al.: Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. J. Clin. Pharmacol. (2006) 46:715-726.","journal-title":"J."},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148604.77591.67"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn938"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.039"},{"key":"e_1_3_1_51_1","first-page":"4292","volume":"281","author":"LEE","year":"2006","unstructured":"LEE EB, LENG LZ, ZHANG B et al.: Targeting amyloid-\u03b2 peptide (A\u03b2) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A\u03b2 precursor protein (APP) transgenic mice. J. Biol. Chem. (2006) 281:4292-4299.","journal-title":"J."},{"key":"e_1_3_1_52_1","first-page":"193","volume":"116","author":"LEVITES","year":"2006","unstructured":"LEVITES Y, DAS P, PRICE RW et al.: Anti-A\u03b242- and anti-A\u03b240-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. (2006) 116:193-201","journal-title":"J."},{"key":"e_1_3_1_53_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nbd.2005.10.002","volume":"22","author":"KULIC","year":"2006","unstructured":"KULIC L, KUROSINSKI P, CHEN F et al.: Active immunization trial in A\u03b242-injected P301L tau transgenic mice. Neurobiol. Dis. (2006) 22:50-56.","journal-title":"Neurobiol."},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000198762.41312.E1"},{"key":"e_1_3_1_55_1","first-page":"126","volume":"28","author":"SIEMERS","year":"2005","unstructured":"SIEMERS E, SKINNER M, DEAN RA et al.: Safety, tolerability, and changes in amyloid \u03b2 concentrations after administration of a \u03b3-secretase inhibitor in volunteers. Clin. Neuropharmacol. (2005) 28:126-132.","journal-title":"Clin"},{"key":"e_1_3_1_56_1","first-page":"17670","volume":"281","author":"WHITE","year":"2006","unstructured":"WHITE AR, DU T, LAUGHTON KM et al.: Degradation of the Alzheimer disease amyloid \u03b2-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. (2006) 281:17670-80","journal-title":"J."},{"key":"e_1_3_1_57_1","first-page":"866","volume":"43","author":"TAKASU","year":"2003","unstructured":"TAKASU T: SMON \u2013 a model of the iatrogenic disease. Rinsho Shinkeigaku (2003) 43:866-869.","journal-title":"Rinsho"},{"key":"e_1_3_1_58_1","first-page":"99","volume":"6","author":"HUCKLE","year":"2005","unstructured":"HUCKLE R. PBT-1 Prana Biotechnology. Curr. Opin. Investig. Drugs (2005) 6:99-107.","journal-title":"Curr."},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0602-541a"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020018"},{"key":"e_1_3_1_61_1","first-page":"343","volume":"2","author":"SPARKS","year":"2005","unstructured":"SPARKS DL, SABBAGH MN, CONNOR DJ et al.: Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. (2005) 2:343-353.","journal-title":"Curr."},{"key":"e_1_3_1_62_1","first-page":"950","volume":"13","author":"WATSON","year":"2005","unstructured":"WATSON GS, CHOLERTON BA, REGER MA et al.: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry (2005) 13:950-958.","journal-title":"Am. J."},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317010-00003"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:26:3:317"},{"key":"e_1_3_1_65_1","first-page":"447","volume":"176","author":"CASADESUS","year":"2006","unstructured":"CASADESUS G, WEBBER KM, ATWOOD CS et al.: Luteinizing hormone modulates cognition and amyloid-\u03b2 deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta (2006) 176(2):447-452.","journal-title":"Biochim"},{"key":"e_1_3_1_66_1","first-page":"WI 152","author":"ABDUL-HAY","year":"2006","unstructured":"ABDUL-HAY S, SUTHERLAND JR, REYNOLDS JN et al.: GT 1061, a novel nitrate ester in clinical trials for Alzheimer's disease, enhances cognitive performance in rats with forebrain cholinergic depletion. 37th Great Lakes Regional Meeting Milwaukee, USA (31 May \u2013 2 June 2006):WI 152.","journal-title":"37th Great Lakes Regional Meeting"},{"key":"e_1_3_1_67_1","first-page":"171","volume":"2","author":"THATCHER","year":"2005","unstructured":"THATCHER GR, BENNET BM, REYNOLDS JS: Nitric oxide mimetic molecules as therapeutic agents in Alzheimer\u2019s disease. Curr. Alzheimer Res. (2005) 2:171-182.","journal-title":"Curr"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2005.08.012"},{"key":"e_1_3_1_69_1","first-page":"252","volume":"314","author":"HIRATA","year":"2005","unstructured":"HIRATA K, YAMAGUCHI Y, TAKAGI A et al.: A novel neurotrophic agent, T-817MA [1-3-[2-(1-benzothiophen- 5-yl)ethoxy]propyl-3-azetidinol maleate], attenuates amyloid-\u03b2-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J. Pharmacol. Exp. Ther. (2005) 314:252-259.","journal-title":"J."},{"key":"e_1_3_1_70_1","first-page":"1015","volume":"305","author":"PAUWELS","year":"2003","unstructured":"PAUWELS PJ, RAULY I, WURCH T: Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated \u03b12A-adrenoreceptor states: evidence for effector pathway-dependent differential antagonism. J. Pharmacol. Exp. Ther. (2003) 305:1015-1023.","journal-title":"J."},{"key":"e_1_3_1_71_1","first-page":"384","volume":"190","author":"DEBEIR","year":"2004","unstructured":"DEBEIR T, MARIEN M, FERRARIO J et al.: In vivo upregulation of endogenous NGF in the rat brain by the \u03b12-adrenoreceptor antagonist dexefaroxan: potential role in the protection of the basolocortical cholinergic system during neurodegeneration. Exp. Neurol. (2004) 190:384-395.","journal-title":"Exp."},{"key":"e_1_3_1_72_1","first-page":"1252","volume":"83","author":"ROCKENSTEIN","year":"2006","unstructured":"ROCKENSTEIN E, TORRANCE M, MANTE M et al.: Cerebrolysin decreases amyloid-\u03b2 production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer\u2019s disease. J. Neurosci. Res. (2006) 83:1252-1261.","journal-title":"J."},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03140-2"},{"key":"e_1_3_1_74_1","first-page":"286","volume":"29","author":"MATA","year":"2006","unstructured":"MATA IF, WEDEMEYER WJ, FARRER MJ et al.: LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. (2006) 29:286-293.","journal-title":"Trends"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.085019"},{"key":"e_1_3_1_76_1","first-page":"210","volume":"63","author":"BLINDAUER","year":"2006","unstructured":"BLINDAUER K, SHOULSON I, OAKES D et al.: Parkinson Study Group: a randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch. Neurol. (2006) 63:210-216.","journal-title":"Arch."},{"key":"e_1_3_1_77_1","first-page":"25","volume":"7","author":"JOHNSTON","year":"2006","unstructured":"JOHNSTON TH, BROTCHIE JM: Drugs in development for Parkinson\u2019s disease: an update. Curr. Opin. Investing. Drugs (2006) 7:25-32.","journal-title":"Curr"},{"key":"e_1_3_1_78_1","first-page":"729","volume":"14","author":"JENNER","year":"2005","unstructured":"JENNER P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs (2005) 14:729-738.","journal-title":"Expert"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522060-00002"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000134672.44217.F7"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1589"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20124"},{"key":"e_1_3_1_83_1","first-page":"1","volume":"7","author":"DORAISWAMY","year":"2006","unstructured":"DORAISWAMY PM, XIONG GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin. Pharmacother. (2006) 7(1):1-10.","journal-title":"Expert"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.09.014"},{"key":"e_1_3_1_85_1","first-page":"58","volume":"27","author":"OLANOW","year":"2004","unstructured":"OLANOW CW, DAMIER P, GOETZ CG et al.: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. (2004) 27:58-62.","journal-title":"Clin"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10464"},{"key":"e_1_3_1_87_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","volume":"15","author":"HADJ","year":"2004","unstructured":"HADJ TAHAR A, GREGOIRE L, DARRE A et al.: Effect of a selective glutamate antagonist on l-DOPA-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. (2004) 15:171-176.","journal-title":"Neurobiol"},{"key":"e_1_3_1_88_1","first-page":"459","volume":"59","author":"LANG","year":"2006","unstructured":"LANG AE, GILL S, PATEL NK et al.: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. (2006) 59:459-466.","journal-title":"Ann."},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.3727\/000000006783982025"},{"key":"e_1_3_1_90_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","volume":"109","author":"CLIFFORD","unstructured":"CLIFFORD JJ, DRAGO J, NATOLI AL et al.: Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience (2002)109:81-88.","journal-title":"Neuroscience"},{"key":"e_1_3_1_91_1","first-page":"127","volume":"4","author":"ASANO","year":"2005","unstructured":"ASANO T, MORI T, SHIMODA T et al.: Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr. Drug Targets CNS Neurol. Disord. (2005) 4:127-142.","journal-title":"Curr"},{"key":"e_1_3_1_92_1","first-page":"70","volume":"7","author":"ORRELL","year":"2006","unstructured":"ORRELL RW: AEOL-10150 (Aeolus). Curr. Opin. Investig. Drugs (2006) 7:70-80.","journal-title":"Curr"},{"key":"e_1_3_1_93_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418150-00003"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1159\/000092329"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300902"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501775200"},{"key":"e_1_3_1_97_1","first-page":"1363","volume":"95","author":"LIU","year":"2005","unstructured":"LIU F, GONG X, MARQUIS K et al.: The inhibition of glycogen synthase kinase 3\u03b2 by metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to A\u03b2 peptides. J. Neurochem. (2005) 95:1363-1372.","journal-title":"J."},{"key":"e_1_3_1_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-005-8826-8"},{"key":"e_1_3_1_99_1","first-page":"17160","volume":"102","author":"KIMURA","year":"2005","unstructured":"KIMURA T, SUGIMORI M, LLINAS RR: Purkinje cell long-term depression is prevented by T-588, a neuroprotective compound that reduces cytosolic calcium release from intracellular stores. Proc. Natl. Acad. Sci. USA (2005) 102:17160-17165.","journal-title":"Proc."},{"key":"e_1_3_1_100_1","first-page":"237","volume":"21","author":"GONZALEZ","year":"2001","unstructured":"GONZALEZ DENISELLE MC, GONZALEZ SL, DE NICOLA AF: Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. Cell. Mol. Neurobiol. (2001) 21:237-254.","journal-title":"Cell. Mol."},{"key":"e_1_3_1_101_1","first-page":"1067","volume":"301","author":"FERZAZ","year":"2002","unstructured":"FERZAZ B, BRAULT E, BOURLIAUD G et al.: SSR180575 (7-chloro-N,N,5- trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J. Pharmacol. Exp. Ther. (2002) 301:1067-1078.","journal-title":"J."},{"key":"e_1_3_1_102_1","first-page":"712","volume":"18","author":"NIRMALANANTHAN","year":"2005","unstructured":"NIRMALANANTHAN N, GREENSMITH L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr. Opin. Neurol. (2005) 18:712-719.","journal-title":"Curr"},{"key":"e_1_3_1_103_1","first-page":"293","volume":"27","author":"ZEMKE","year":"2004","unstructured":"ZEMKE D, MAJID A: The potential of minocycline for neuroprotection in human neurologic disease. Clin. Neuropharmacol. (2004) 27:293-298.","journal-title":"Clin"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519120-00002"},{"key":"e_1_3_1_105_1","first-page":"1967","volume":"6","author":"CACABELOS","year":"2005","unstructured":"CACABELOS R: Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin. Pharmacother. (2005) 6:1967-1987.","journal-title":"Expert"},{"key":"e_1_3_1_106_1","first-page":"639","volume":"9","author":"HANNAN","year":"2005","unstructured":"HANNAN AJ: Novel therapeutic targets for Huntington's disease. Expert Opin. Ther. Targets (2005) 9:639-650.","journal-title":"Expert"},{"key":"e_1_3_1_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10364-1"},{"key":"e_1_3_1_108_2_1","unstructured":"http:\/\/www.axonyx.com\/pipeline\/ posiphen.htmlAxonyx website pipeline (2006)."},{"key":"e_1_3_1_108_3_1","unstructured":"http:\/\/www.elan.com\/News\/print_full.asp? ID=594662Elan website news (2006)."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.16.1.59","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:00:12Z","timestamp":1772762412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.16.1.59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,7]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1517\/13543784.16.1.59"],"URL":"https:\/\/doi.org\/10.1517\/13543784.16.1.59","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,7]]}}}